Zhongmin Maxwell Wang (Zhongmin Wang)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 17

Top Topics

Vascular Endothelial Growth Factor

Small Cell Lung Cancer

Top Venues

Journal for immunotherapy of cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature medicine

Signal transduction and targeted therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Wenjing Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine I G Coward
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Xiang-Yu Gao, Ke Ji, Yongning Jia, Fei Shan, Ye Chen, Nong Xu, Ziyu Jia, Tian-Shu Liu, Nong Yang, Haijun Zhong, Changzheng Li, Zengqing Guo, Qingxia Fan, Xiaoyan Lin, Yan Zhang, Hui Ren, Hongxia Yang, Zhifang Yao, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Lin Shen, Zi-Yu Li, Jia Fu Ji
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial. Nature medicine (2024)
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Wenjing Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine I G Coward
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Xiaozhong Chen, Wei Wang, Qingfeng Zou, Xiaodong Zhu, Qin Lin, Yi Jiang, Yan Sun, Liangfang Shen, Lin Wang, Guorong Zou, Xiaoyan Lin, Shaojun Lin, Minying Li, Ying Wang, Ruilian Xu, Rui Ao, Rensheng Wang, Haifeng Lin, Shuang Huang, Tingting Xu, Wenting Li, Mengying Xia, Yu Xia, Zhongmin Maxwell Wang, Baiyong Li, Jingao Li, Chaosu Hu
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. Signal transduction and targeted therapy 9 (1) (2024)
Xiaozhong Chen, Wei Wang, Qingfeng Zou, Xiaodong Zhu, Qin Lin, Yi Jiang, Yan Sun, Liangfang Shen, Lin Wang, Guorong Zou, Xiaoyan Lin, Shaojun Lin, Minying Li, Ying Wang, Ruilian Xu, Rui Ao, Rensheng Wang, Haifeng Lin, Shuang Huang, Tingting Xu, Wenting Li, Mengying Xia, Yu Xia, Zhongmin Maxwell Wang, Baiyong Li, Jingao Li, Chaosu Hu
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. Signal transduction and targeted therapy 9 (1) (2024)
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Xiaozhong Chen, Wei Wang, Qingfeng Zou, Xiaodong Zhu, Qin Lin, Yi Jiang, Yan Sun, Liangfang Shen, Lin Wang, Guorong Zou, Xiaoyan Lin, Shaojun Lin, Minying Li, Ying Wang, Ruilian Xu, Rui Ao, Rensheng Wang, Haifeng Lin, Shuang Huang, Tingting Xu, Wenting Li, Mengying Xia, Yu Xia, Zhongmin Maxwell Wang, Baiyong Li, Jingao Li, Chaosu Hu
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. Signal transduction and targeted therapy 9 (1) (2024)
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Wenjing Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine I G Coward
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Xiang-Yu Gao, Ke Ji, Yongning Jia, Fei Shan, Ye Chen, Nong Xu, Ziyu Jia, Tian-Shu Liu, Nong Yang, Haijun Zhong, Changzheng Li, Zengqing Guo, Qingxia Fan, Xiaoyan Lin, Yan Zhang, Hui Ren, Hongxia Yang, Zhifang Yao, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Lin Shen, Zi-Yu Li, Jia Fu Ji
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial. Nature medicine 30 (7) (2024)
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Wenjing Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine I G Coward
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Wenjing Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine I G Coward
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Xiang-Yu Gao, Ke Ji, Yongning Jia, Fei Shan, Ye Chen, Nong Xu, Ziyu Jia, Tian-Shu Liu, Nong Yang, Haijun Zhong, Changzheng Li, Zengqing Guo, Qingxia Fan, Xiaoyan Lin, Yan Zhang, Hui Ren, Hongxia Yang, Zhifang Yao, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Lin Shen, Zi-Yu Li, Jia Fu Ji
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial. Nature medicine 30 (7) (2024)
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Wenjing Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine I G Coward
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)